Recordati (REC) Stock Price, Fundamentals & Analysis

What REC does

Recordati (REC) is a Milan-based healthcare company that researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. Its portfolio includes treatments for rare diseases such as Maapliv for maple syrup urine disease, Isturia for endogenous Cushing's syndrome, Cystadrops for the ocular manifestations of cystinosis, Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency, Qarziba for neuroblastoma, and Fotivda for renal cell carcinoma, alongside therapies for hypertension, benign prostatic hyperplasia, dyslipidemia, angina, myocardial infarction, and cardiac rhythm disorders.

Key numbers explained

• Price of 53.05 EUR is the most recent trading price on the Borsa Italiana.
• Market capitalization of 10.87B EUR reflects the total market value of all outstanding shares.
• The trailing P/E ratio of 22.3 divides the current share price by the last twelve months of earnings per share (2.38 EUR), showing how much investors pay per euro of recent earnings.
• The forward P/E ratio of 14.1 uses expected future earnings, often a more forward-looking valuation measure.
• Dividend yield of 2.68% indicates the annual dividend payout as a percentage of the current share price.
• The ex-dividend date of May 18, 2026 is the cutoff to own the stock and receive the next dividend.
• Beta of 0.53 suggests the stock has historically been less volatile than the overall market.
• Return on equity of 24.9% measures how effectively the company generates profit from shareholders' equity.

What to watch

Investors tracking REC often compare it with peers such as Amplifon (AMP) and Diasorin (DIA) on the Borsa Italiana stocks page. Revenue growth of 8.3% year over year and a profit margin of 18.4% are common starting points for assessing operational efficiency. The debt-to-equity ratio of 108.6% is a leverage metric that shows the relative weight of debt compared to equity. The price-to-book ratio of 5.1 compares the market price to the company's book value per share. Upcoming events like the next earnings date on Nov 10, 2026 can drive short-term price movement as the market digests new results.